Kiniksa Pharmaceuticals, Ltd. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Financial amounts below are in U.S. dollars; millions are rounded. The filing identifies the registrant as Kiniksa Pharmaceuticals, Ltd.
Business context
Kiniksa is a commercial-stage biopharmaceutical company focused on immune-modulating medicines. Its marketed product is ARCALYST (rilonacept); key development programs include KPL-404 and mavrilimumab. Genentech holds worldwide rights to develop and commercialize vixarelimab, while Kiniksa remains responsible for completing its Phase 2b prurigo nodularis trial.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Product revenue | $64.8m | $33.4m | $162.0m | $82.6m |
| License and collaboration revenue | $2.2m | $65.7m | $24.9m | $75.7m |
| Total revenue | $67.0m | $99.1m | $186.9m | $158.3m |
| Operating income (loss) | $(10.9)m | $46.4m | $(25.3)m | $3.7m |
| Net income (loss) | $(13.9)m | $224.1m | $(11.2)m | $178.9m |
| Operating cash flow | Not provided quarterly | Not provided quarterly | $9.0m | $17.4m |
- ARCALYST revenue increased 94% in Q3 and 96% for the nine-month period, primarily due to more patients. Product revenue less cost of goods sold was $55.7m in Q3 and $138.1m year to date, before collaboration expenses and other operating costs.
- Total revenue declined 32% in Q3 despite product growth because the prior-year quarter included substantial vixarelimab license revenue. Nine-month total revenue rose 18%.
- Operating expenses were $78.0m in Q3 and $212.1m year to date. Higher ARCALYST sales also increased Regeneron collaboration expenses; R&D growth was driven largely by KPL-404, while SG&A increased with commercial and sales-force expansion.
- Prior-year net income included a $177.4m Q3 income tax benefit, principally from releasing a valuation allowance on UK deferred tax assets. In 2023, the nine-month tax benefit was $7.9m, including a $19.2m second-quarter release of the valuation allowance on U.S. deferred tax assets; Q3 itself recorded a $5.4m tax provision.
- Cash, cash equivalents and short-term investments totaled $201.1m at September 30, 2023, versus $190.6m at December 31, 2022. Cash and cash equivalents alone were $117.8m. Current assets were $256.1m and current liabilities $53.5m.
- Operating cash flow was positive $9.0m for nine months, down from $17.4m. Cash and cash equivalents decreased $4.9m; investing activities used $14.7m, mainly reflecting purchases of short-term investments net of maturities.
- The balance sheet lists no borrowings; operating lease liabilities were $13.0m in total. This does not include the company’s substantial contractual manufacturing commitments.
Material changes, outlook and key risks
- Management expects existing cash, cash equivalents and short-term investments to fund operations and capital expenditures for at least 12 months from the financial statements’ issuance date. The company expects operating losses for the foreseeable future; no specific revenue or earnings guidance is provided.
- ARCALYST drug-substance manufacturing technology transfer from Regeneron to a new CDMO is underway. Kiniksa selected a replacement CDMO and testing labs, but transfer, comparability, regulatory approval, timing, cost and sufficient interim supply remain risks.
- Manufacturing commitments totaled $133.7m at September 30, of which $56.8m was due within one year. The filing separately identifies $97.5m for ARCALYST technology transfer and $24.9m of Regeneron supply commitments, alongside other clinical-supply commitments.
- KPL-404’s Phase 2 rheumatoid arthritis trial had completed enrollment of its third cohort by October 2023; the fourth cohort was enrolling. Management expected data from the first three cohorts in Q1 2024 and the fourth cohort in Q2 2024.
- Genentech paid $15.0m following a development milestone in Q2 2023, received by Kiniksa in Q3. Approximately $585m of potential contingent Genentech payments remained, before upstream obligations; these payments are conditional, not assured revenue.
- Management cites reliance on ARCALYST, reimbursement and market acceptance, clinical-trial uncertainty, competition, third-party manufacturing and supply, and the need for future capital if sales or other funding prove insufficient. A large private insurer had excluded ARCALYST for CAPS in January 2023, which Kiniksa says could create coverage hurdles more broadly.
- No material litigation was reported. Disclosure controls were assessed as effective, and the filing reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether ARCALYST patient growth and revenue momentum continue, and how payor coverage, rebates and Regeneron’s profit share affect economics.
- Progress, cost, regulatory acceptance and supply continuity for the ARCALYST manufacturing transfer, including the $133.7m commitments and near-term payment schedule.
- KPL-404 trial timing and results, and whether management’s stated 2024 data milestones are achieved.
- Cash consumption, the stated 12-month liquidity runway, and whether additional financing may be needed; operating cash flow was positive despite operating losses.
- Whether collaboration milestones and royalties generate future cash, distinguishing contingent payments from recognized revenue and cash already received.